PRDM15

Across TCGA pan-cancer cohorts, PRDM15 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PRDM15 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRDM15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRDM15 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, SKCM, and LIHC are the cancer types where PRDM15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.181	0.549	.001	27	view →
SKCM	DFS	Median	II,III,IV	0.889	0.676	.018	12	view →
LIHC	OS	Median	All	0.025	0.775	<.001	9	view →
GBM	OS	Median	All	0.030	0.416	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
HNSC	OS	Median	III,IV	0.174	0.656	.040	6	view →
CESC	OS	Median	All	0.684	0.876	.045	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PRDM15–BLCA (OS)

Open the BLCA breakdown →